The recent Nasdaq entrant prepares to move AKY-2519 into the clinic.
ApexOnco Front Page
Recent articles
The phase 2/3 Revival trial will test a ven/aza combo in first-line AML.
The line-up is revealed to include Merck & Co and J&J itself.
A phase 1 study of OKI-219 reads out imminently.
The latest onvansertib data, and an abrupt CEO departure, spook investors.
Bristol will test the bispecific in two new lung indications.
New pivotal trials of HRS-8080 are planned in first-line and adjuvant breast cancer.
After Genmab’s exit two more ADCs enter human trials.
